| human | Q5 |
| P496 | ORCID iD | 0000-0002-6139-3632 |
| P69 | educated at | University of Sydney | Q487556 |
| Royal Australasian College of Physicians | Q7373726 | ||
| P735 | given name | Ian | Q18336315 |
| Ian | Q18336315 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q46005132 | Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial. |
| Q37277912 | Association of hypoglycemic treatment regimens with cardiovascular outcomes in overweight and obese subjects with type 2 diabetes: a substudy of the SCOUT trial |
| Q58175609 | Body Fatness and Cardiovascular Health in Newborn Infants |
| Q44471524 | Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial |
| Q37616624 | Continuous exercise but not high intensity interval training improves fat distribution in overweight adults |
| Q37402140 | Differential changes in serum uric acid concentrations in sibutramine promoted weight loss in diabetes: results from four weeks of the lead-in period of the SCOUT trial |
| Q43264779 | Early response to sibutramine in patients not meeting current label criteria: preliminary analysis of SCOUT lead-in period |
| Q64108751 | Effect of Fish Oil Supplementation on Hepatic and Visceral Fat in Overweight Men: A Randomized Controlled Trial |
| Q41088412 | Effect of aerobic exercise training dose on liver fat and visceral adiposity. |
| Q53775541 | Effect of resistance training on liver fat and visceral adiposity in adults with obesity: A randomized controlled trial. |
| Q34136304 | Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects |
| Q61477940 | Efficacy of the Omega-3 Index in predicting non-alcoholic fatty liver disease in overweight and obese adults: a pilot study |
| Q36207931 | Ethnic comparisons of obesity in the Asia-Pacific region: protocol for a collaborative overview of cross-sectional studies. |
| Q91588355 | Gaps to bridge: Misalignment between perception, reality and actions in obesity |
| Q89421188 | Greater improvements in diet quality among overweight participants following a group-based commercial weight loss programme than those receiving support to lose weight in primary care |
| Q52693062 | Less Waste on Waist Measurements: Determination of Optimal Waist Circumference Measurement Site to Predict Visceral Adipose Tissue in Postmenopausal Women with Obesity. |
| Q64063201 | Modelling the Association between Core and Discretionary Energy Intake in Adults with and without Obesity |
| Q35686100 | Modelling the Interplay between Lifestyle Factors and Genetic Predisposition on Markers of Type 2 Diabetes Mellitus Risk |
| Q37335236 | Objectively Quantified Physical Activity and Sedentary Behavior in Predicting Visceral Adiposity and Liver Fat |
| Q35515066 | Primary care referral to a commercial provider for weight loss treatment versus standard care: a randomised controlled trial |
| Q47160543 | Quantity and Quality of Carbohydrate Intake during Pregnancy, Newborn Body Fatness and Cardiac Autonomic Control: Conferred Cardiovascular Risk? |
| Q61766547 | Rationale and Protocol for a Randomized Controlled Trial Comparing Fast versus Slow Weight Loss in Postmenopausal Women with Obesity-The TEMPO Diet Trial |
| Q61974635 | Recruitment Strategies for a Randomised Controlled Trial Comparing Fast Versus Slow Weight Loss in Postmenopausal Women with Obesity-The TEMPO Diet Trial |
| Q39203044 | Relation between weight loss and causes of death in patients with cardiovascular disease: finding from the SCOUT trial |
| Q115761127 | Single-gene long-read sequencing illuminates Escherichia coli strain dynamics in the human intestinal microbiome |
| Q97516857 | Targeting the Intestinal Microbiota to Prevent Type 2 Diabetes and Enhance the Effect of Metformin on Glycaemia: A Randomised Controlled Pilot Study |
| Q33534537 | The weight lowering effect of sibutramine and its impact on serum lipids in cardiovascular high risk patients with and without type 2 diabetes mellitus - an analysis from the SCOUT lead-in period |
| Q46228586 | Tolerability of sibutramine during a 6-week treatment period in high-risk patients with cardiovascular disease and/or diabetes: a preliminary analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial |
| Q34637721 | Uric acid as a risk factor for cardiovascular disease and mortality in overweight/obese individuals |
| Q62909609 | Waist Circumference Thresholds Provide an Accurate and Widely Applicable Method for the Discrimination of Diabetes |
Search more.